AU Stock MarketDetailed Quotes
PTX Prescient Therapeutics Ltd
- 0.045
- 0.0000.00%
20min DelayMarket Closed May 31 16:00 AET
36.24MMarket Cap-4500P/E (Static)
0.045High0.044Low166.52KVolume0.044Open0.045Pre Close7.34KTurnover0.10552wk High0.02%Turnover Ratio805.32MShares0.04052wk Low-0.01EPS TTM30.98MFloat Cap83183.120Historical HighLossP/E (Static)688.51MShs Float0.022Historical Low-0.01EPS LYR2.22%Amplitude--Dividend TTM1.61P/B1Lot Size--Div YieldTTM
About Prescient Therapeutics Ltd Company
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Company Profile
SymbolPTX
Company NamePrescient Therapeutics Ltd
Founded1986
MarketASX
Employees1
Fiscal Year Ends06-30
AddressLevel 4, 100 Albert Road South Melbourne
CityMelbourne
CountryAustralia
Zip Code3205
Phone+61 396927222
Company Executives
- Name
- Position
- Salary
- Steven Yatomi-Clarke
- Chief Executive Officer,Managing Director
- --
- Steven (Steve) Barnard Engle
- Non-Executive Chairman,Non-Executive Director
- --
- James Campbell
- Non-Executive Director
- --
- Ellen Gwen Feigal
- Non-Executive Director
- --
- Allen James Ebens
- Non-Executive Director
- --
Analysis
Price Target
No Data
Heat List
AU
Overall
Symbol
Latest Price
%Chg